HAI Book 2025 - Flipbook - Page 589
Discussion: Brain atrophy may affect accurate neuroradiological diagnosis and/or quantification of amyloid PET
positivity in early AD. Suboptimal sensitivity of amyloid PET clinical assessments may delay care and in research
may bias sampling, especially in those participants who are nearest a binary cutoff, early in the disease course.
This may present a bias against participants with comorbidities that accelerate the onset of
neurodegeneration[1]. Assessment of atrophy is advised especially in those with borderline amyloid positivity.
Keywords: neurodegeneration, PET quantification, clinical PET positivity determination
HAI2025 - 589
